Synairgen Supercharges R&D With $100m Financing
To Support COVID-19 Study Of Inhaled Beta-Interferon
With a candidate COVID-19 therapy in clinical development, the UK’s Synairgen has raised $101m on the UK’s AIM to support clinical studies and manufacturing plans.
You may also be interested in...
The UK company surged on early results in the summer – but must prove its therapy’s impact in a Phase III study
The UK’s biotech sector sees investor interest surge during the pandemic, though IPO levels are still disappointing compared with recent years.
Walmsley has been awarded a damehood in the Queen’s Birthday Honours List. Meanwhile, Synairgen co-founder Holgate is to become a Sir.